Phase 3 · 68 weeks
STEP 1
Wegovy injection- Semaglutide 2.4 mg
- −14.9%
- Placebo
- −2.4%
DarDoc Research
GLP-1 Trial & Approval Tracker
GLP-1 weight loss in clinical trials
See published weight change by dose and follow-up, then explore response rates and safety by study.
Published results
Charts by trial
15 trials
Phase 3 · 72 weeks
SURMOUNT-1
Mounjaro- Tirzepatide 5 mg
- −15.0%
- Tirzepatide 10 mg
- −19.5%
- Tirzepatide 15 mg
- −20.9%
- Placebo
- −3.1%
Phase 3b · 64 weeks
OASIS 4
Wegovy tablets- Oral semaglutide 25 mg
- −13.6%
- Placebo
- −2.2%
Phase 3 · 72 weeks
ATTAIN-1
Foundayo- Orforglipron 6 mg
- −7.5%
- Orforglipron 12 mg
- −8.4%
- Orforglipron 36 mg
- −11.2%
- Placebo
- −2.1%
Phase 3b · 72 weeks
SURMOUNT-5
MounjaroWegovy injection- Tirzepatide 10 or 15 mg
- −20.2%
- Semaglutide 1.7 or 2.4 mg
- −13.7%
Phase 3 · 104 weeks
STEP 5
Wegovy injection- Semaglutide 2.4 mg
- −15.2%
- Placebo
- −2.6%
Phase 3 · 72 weeks
SURMOUNT-2
Mounjaro- Tirzepatide 10 mg
- −12.8%
- Tirzepatide 15 mg
- −14.7%
- Placebo
- −3.2%
Phase 3 · 72 weeks
ATTAIN-J
Foundayo- Orforglipron 6 mg
- −5.9%
- Orforglipron 12 mg
- −8.7%
- Orforglipron 36 mg
- −7.9%
- Placebo
- −0.6%
Phase 3 · 72 weeks
ATTAIN-2
Foundayo- Orforglipron 6 mg
- −5.1%
- Orforglipron 12 mg
- −7.0%
- Orforglipron 36 mg
- −9.6%
- Placebo
- −2.5%
Phase 3b · 72 weeks
STEP UP
Wegovy injection- Semaglutide 7.2 mg
- −18.7%
- Semaglutide 2.4 mg
- −15.6%
- Placebo
- −3.9%
Phase 3a · 68 weeks
REDEFINE 1
CagriSemaWegovy injection- CagriSema 2.4 mg / 2.4 mg
- −20.4%
- Semaglutide 2.4 mg
- −14.9%
- Cagrilintide 2.4 mg
- −11.5%
- Placebo
- −3.0%
Phase 3 · 32 weeks
GLORY-1
Mazdutide- Mazdutide 4 mg
- −10.09%
- Mazdutide 6 mg
- −12.55%
- Placebo
- +0.45%
Phase 3 · 76 weeks
SYNCHRONIZE-1
Survodutide- Survodutide up to 3.6 mg
- −12.2%
- Survodutide up to 6.0 mg
- −13.0%
- Placebo
- −5.4%
Phase 2 · 24 weeks
Retatrutide phase 2
Retatrutide- Retatrutide 1 mg
- −7.2%
- Retatrutide 4 mg (pooled)
- −12.9%
- Retatrutide 8 mg (pooled)
- −17.3%
- Retatrutide 12 mg
- −17.5%
- Placebo
- −1.6%
Phase 3 · 80 weeks
TRIUMPH-1
Retatrutide- Retatrutide 4 mg
- −17.6%
- Retatrutide 9 mg
- −23.7%
- Retatrutide 12 mg
- −25.0%
- Placebo
- −3.9%
Each chart shows the arms within one trial. Follow-up and eligibility vary across studies.
Explore one study
STEP 1
Wegovy injectionWithout diabetes · 68 weeks · n=1,961
Double-blind, placebo-controlled. Treatment-policy analysis.
- Semaglutide 2.4 mg−14.9%
- Placebo−2.4%